GeneDx (NASDAQ:WGS) Receives Sell (D) Rating from Weiss Ratings

Key Points

• GeneDx's stock received a "sell (D)" rating from Weiss Ratings, indicating potential concerns regarding its future performance.
• Despite the negative rating from Weiss, other analysts have shown bullish sentiment, with eight analysts rating it a Buy and raising price targets significantly, leading to a consensus target price of $112.80.
• GeneDx's stock has seen substantial trading activity, reaching a price of $128.87 with a market capitalization of $3.70 billion, reflecting notable volatility over the past year.

GeneDx (NASDAQ:WGS - Get Free Report)'s stock had its "sell (d)" rating reaffirmed by equities researchers at Weiss Ratings in a report released on Friday,Weiss Ratings reports.

Other equities research analysts have also issued research reports about the company. Wells Fargo & Company boosted their price objective on GeneDx from $78.00 to $95.00 and gave the stock an "equal weight" rating in a research report on Wednesday, July 30th. Wall Street Zen upgraded GeneDx from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. BTIG Research boosted their price objective on GeneDx from $125.00 to $140.00 and gave the stock a "buy" rating in a research report on Wednesday. Piper Sandler boosted their price objective on GeneDx from $120.00 to $140.00 and gave the stock an "overweight" rating in a research report on Thursday, September 11th. Finally, Guggenheim restated a "buy" rating and set a $115.00 price objective (up previously from $88.00) on shares of GeneDx in a research report on Monday, June 30th. Eight equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, GeneDx currently has an average rating of "Moderate Buy" and a consensus target price of $112.80.

GeneDx Price Performance

Shares of WGS traded up $3.80 during midday trading on Friday, hitting $128.87. The company's stock had a trading volume of 482,810 shares, compared to its average volume of 938,551. GeneDx has a one year low of $55.17 and a one year high of $136.00. The company's fifty day simple moving average is $123.17 and its two-hundred day simple moving average is $97.35. The company has a quick ratio of 2.70, a current ratio of 2.87 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $3.70 billion, a price-to-earnings ratio of 2,577.40 and a beta of 1.98.

GeneDx (NASDAQ:WGS - Get Free Report) last issued its quarterly earnings results on Tuesday, July 29th. The company reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $0.40. GeneDx had a return on equity of 16.51% and a net margin of 0.39%.The company had revenue of $102.69 million for the quarter, compared to analyst estimates of $86.00 million. GeneDx has set its FY 2025 guidance at EPS. As a group, equities analysts expect that GeneDx will post 0.97 earnings per share for the current fiscal year.

Insider Buying and Selling

In other GeneDx news, CEO Katherine Stueland sold 10,501 shares of GeneDx stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $121.47, for a total transaction of $1,275,556.47. Following the transaction, the chief executive officer directly owned 14,578 shares of the company's stock, valued at approximately $1,770,789.66. The trade was a 41.87% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Casdin Capital, Llc sold 500,000 shares of GeneDx stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $120.90, for a total value of $60,450,000.00. Following the transaction, the director directly owned 3,007,164 shares in the company, valued at $363,566,127.60. The trade was a 14.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 556,371 shares of company stock valued at $67,489,314 over the last 90 days. 29.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of WGS. GAMMA Investing LLC lifted its holdings in GeneDx by 151.7% during the 1st quarter. GAMMA Investing LLC now owns 438 shares of the company's stock worth $39,000 after buying an additional 264 shares during the period. US Bancorp DE lifted its holdings in GeneDx by 3,223.5% during the 1st quarter. US Bancorp DE now owns 565 shares of the company's stock worth $50,000 after buying an additional 548 shares during the period. AlphaQuest LLC lifted its stake in shares of GeneDx by 351.5% in the 2nd quarter. AlphaQuest LLC now owns 763 shares of the company's stock valued at $70,000 after purchasing an additional 594 shares during the period. KBC Group NV acquired a new position in shares of GeneDx in the 1st quarter valued at about $81,000. Finally, PNC Financial Services Group Inc. acquired a new position in shares of GeneDx in the 1st quarter valued at about $132,000. 61.72% of the stock is owned by institutional investors and hedge funds.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.